microRNA information: hsa-miR-502-3p
| Section | ID | link |
|---|---|---|
| Mature name: | hsa-miR-502-3p | miRbase |
| Accession: | MIMAT0004775 | miRbase |
| Precursor name: | hsa-mir-502 | miRbase |
| Precursor accession: | MI0003186 | miRbase |
| Symbol: | MIR502 | HGNC |
| RefSeq ID: | NR_030226 | GenBank |
| Sequence: | AAUGCACCUGGGCAAGGAUUCA |
Reported expression in cancers: hsa-miR-502-3p
| miRNA | cancer | regulation | reporting | PUBMED | method |
|---|---|---|---|---|---|
| hsa-miR-502-3p | colon cancer | downregulation | "Inhibition of autophagy and tumor growth in colon ......" | 22580605 |
Reported cancer pathway affected by hsa-miR-502-3p
| miRNA | cancer | pathway | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-502-3p | breast cancer | cell cycle pathway | "Our previous research and extensive epidemiologica ......" | 27080302 | |
| hsa-miR-502-3p | colon cancer | cell cycle pathway | "Inhibition of autophagy and tumor growth in colon ......" | 22580605 | |
| hsa-miR-502-3p | esophageal cancer | Apoptosis pathway | "miR 502 medaited histone methyltransferase SET8 ex ......" | 27605386 | |
| hsa-miR-502-3p | liver cancer | cell cycle pathway; Apoptosis pathway | "miR 502 inhibits cell proliferation and tumor grow ......" | 26163264 |
Reported cancer prognosis affected by hsa-miR-502-3p
| miRNA | cancer | prognosis | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-502-3p | breast cancer | cell migration | "Our previous research and extensive epidemiologica ......" | 27080302 | |
| hsa-miR-502-3p | colon cancer | progression | "Inhibition of autophagy and tumor growth in colon ......" | 22580605 | |
| hsa-miR-502-3p | esophageal cancer | poor survival | "miR 502 medaited histone methyltransferase SET8 ex ......" | 27605386 | |
| hsa-miR-502-3p | lung squamous cell cancer | poor survival | "Genetic variation in a microRNA 502 minding site i ......" | 24146953 | Luciferase |
Reported gene related to hsa-miR-502-3p
| miRNA | cancer | gene | reporting | PUBMED |
|---|---|---|---|---|
| hsa-miR-502-3p | breast cancer | SETD8 | "Our previous research and extensive epidemiologica ......" | 27080302 |
| hsa-miR-502-3p | breast cancer | SETD8 | "An miR 502 binding site single nucleotide polymorp ......" | 19789321 |
| hsa-miR-502-3p | cervical and endocervical cancer | SETD8 | "Association of a miR 502 binding site single nucle ......" | 25169478 |
| hsa-miR-502-3p | esophageal cancer | SETD8 | "miR 502 medaited histone methyltransferase SET8 ex ......" | 27605386 |
| hsa-miR-502-3p | kidney renal cell cancer | SETD8 | "Polymorphism at the miR 502 binding site in the 3' ......" | 27346408 |
| hsa-miR-502-3p | liver cancer | SETD8 | "A polymorphism at the miR 502 binding site in the ......" | 22095217 |
| hsa-miR-502-3p | lung squamous cell cancer | SETD8 | "A polymorphism at the miR 502 binding site in the ......" | 22969952 |
| hsa-miR-502-3p | lung squamous cell cancer | SETD8 | "Genetic variation in a microRNA 502 minding site i ......" | 24146953 |
| hsa-miR-502-3p | lung squamous cell cancer | SETD8 | "Association of miR 502 binding site single nucleot ......" | 24374662 |
| hsa-miR-502-3p | lymphoma | SETD8 | "Prognostic value of microRNA 502 binding site SNP ......" | 25343552 |
| hsa-miR-502-3p | ovarian cancer | SETD8 | "A polymorphism at the miR 502 binding site in the ......" | 22867998 |
| hsa-miR-502-3p | cervical and endocervical cancer | TP53 | "Association of a miR 502 binding site single nucle ......" | 25169478 |
| hsa-miR-502-3p | colon cancer | TP53 | "In addition the expression of miR-502 was regulate ......" | 22580605 |
| hsa-miR-502-3p | lung squamous cell cancer | TP53 | "Association of miR 502 binding site single nucleot ......" | 24374662 |
| hsa-miR-502-3p | colon cancer | DHODH | "A number of other miR-502 suppressed mRNA targets ......" | 22580605 |
| hsa-miR-502-3p | liver cancer | PIK3CG | "Phosphoinositide 3-kinase catalytic subunit gamma ......" | 26163264 |
| hsa-miR-502-3p | colon cancer | RAB1B | "In this study we discover a novel mechanism of aut ......" | 22580605 |
| hsa-miR-502-3p | lymphoma | RTEL1 | "We evaluated the effect of single-nucleotide polym ......" | 25343552 |
| hsa-miR-502-3p | lung squamous cell cancer | SCLC1 | "We analysed a single nucleotide polymorphism rs169 ......" | 22969952 |
| hsa-miR-502-3p | breast cancer | TRAF2 | "Suppressive role of miR 502 5p in breast cancer vi ......" | 24677135 |
Expression profile in cancer corhorts:
Putative target regulations
| miRNA | Gene | Cancer | Interaction | Correlation beta |
|---|---|---|---|---|
hsa-miR-502-3p | ZSWIM6 | 9 cancers: BLCA; BRCA; COAD; KIRC; KIRP; LGG; LIHC; LUAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.146; TCGA BRCA -0.156; TCGA COAD -0.08; TCGA KIRC -0.122; TCGA KIRP -0.145; TCGA LGG -0.095; TCGA LIHC -0.195; TCGA LUAD -0.141; TCGA STAD -0.181 |
hsa-miR-502-3p | AFF4 | 9 cancers: BLCA; BRCA; COAD; HNSC; LGG; LIHC; LUAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.136; TCGA BRCA -0.258; TCGA COAD -0.159; TCGA HNSC -0.149; TCGA LGG -0.077; TCGA LIHC -0.188; TCGA LUAD -0.07; TCGA SARC -0.093; TCGA STAD -0.212 |
hsa-miR-502-3p | CLIC4 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; PAAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.229; TCGA CESC -0.198; TCGA COAD -0.428; TCGA ESCA -0.421; TCGA HNSC -0.175; TCGA LIHC -0.099; TCGA LUAD -0.151; TCGA PAAD -0.303; TCGA SARC -0.155; TCGA STAD -0.525 |
hsa-miR-502-3p | NBR1 | 11 cancers: BLCA; BRCA; KIRP; LIHC; LUSC; OV; PAAD; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.124; TCGA BRCA -0.212; TCGA KIRP -0.08; TCGA LIHC -0.211; TCGA LUSC -0.067; TCGA OV -0.064; TCGA PAAD -0.076; TCGA PRAD -0.087; TCGA SARC -0.072; TCGA STAD -0.085; TCGA UCEC -0.095 |
hsa-miR-502-3p | CCDC50 | 11 cancers: BLCA; CESC; COAD; HNSC; KIRC; KIRP; LGG; PAAD; SARC; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.158; TCGA CESC -0.208; TCGA COAD -0.116; TCGA HNSC -0.102; TCGA KIRC -0.196; TCGA KIRP -0.165; TCGA LGG -0.122; TCGA PAAD -0.147; TCGA SARC -0.1; TCGA STAD -0.302; TCGA UCEC -0.07 |
hsa-miR-502-3p | ZFHX4 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRP; LGG; LUSC; OV; PAAD; STAD | MirTarget; PITA; miRNATAP | TCGA BLCA -0.536; TCGA BRCA -0.304; TCGA CESC -0.469; TCGA COAD -0.853; TCGA ESCA -0.892; TCGA KIRP -0.547; TCGA LGG -0.14; TCGA LUSC -0.462; TCGA OV -0.213; TCGA PAAD -0.555; TCGA STAD -0.803 |
hsa-miR-502-3p | RBMS1 | 12 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; OV; PAAD; STAD; UCEC | MirTarget; PITA; miRNATAP | TCGA BLCA -0.108; TCGA CESC -0.202; TCGA COAD -0.521; TCGA ESCA -0.46; TCGA HNSC -0.145; TCGA KIRP -0.061; TCGA LIHC -0.283; TCGA LUAD -0.061; TCGA OV -0.065; TCGA PAAD -0.425; TCGA STAD -0.378; TCGA UCEC -0.133 |
hsa-miR-502-3p | CDH6 | 9 cancers: BLCA; BRCA; COAD; KIRC; KIRP; LIHC; LUAD; LUSC; THCA | MirTarget | TCGA BLCA -0.214; TCGA BRCA -0.201; TCGA COAD -0.334; TCGA KIRC -0.886; TCGA KIRP -0.725; TCGA LIHC -0.343; TCGA LUAD -0.24; TCGA LUSC -0.263; TCGA THCA -0.778 |
hsa-miR-502-3p | SEMA3C | 13 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; PAAD; THCA; STAD; UCEC | MirTarget; PITA; miRNATAP | TCGA BLCA -0.281; TCGA BRCA -0.559; TCGA CESC -0.229; TCGA ESCA -0.539; TCGA HNSC -0.328; TCGA KIRP -0.526; TCGA LIHC -0.366; TCGA LUAD -0.147; TCGA LUSC -0.281; TCGA PAAD -0.537; TCGA THCA -0.265; TCGA STAD -0.62; TCGA UCEC -0.185 |
hsa-miR-502-3p | UBE2H | 12 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; PAAD; THCA; STAD | MirTarget; PITA; miRNATAP | TCGA BLCA -0.084; TCGA BRCA -0.171; TCGA COAD -0.08; TCGA ESCA -0.161; TCGA HNSC -0.182; TCGA KIRP -0.167; TCGA LIHC -0.094; TCGA LUAD -0.101; TCGA LUSC -0.112; TCGA PAAD -0.112; TCGA THCA -0.097; TCGA STAD -0.115 |
hsa-miR-502-3p | CYP27C1 | 11 cancers: BLCA; COAD; ESCA; HNSC; KIRP; LGG; LUAD; LUSC; PAAD; STAD; UCEC | MirTarget | TCGA BLCA -0.668; TCGA COAD -0.633; TCGA ESCA -1.404; TCGA HNSC -0.537; TCGA KIRP -0.395; TCGA LGG -0.407; TCGA LUAD -0.576; TCGA LUSC -0.926; TCGA PAAD -0.989; TCGA STAD -0.688; TCGA UCEC -0.308 |
hsa-miR-502-3p | KCNT2 | 9 cancers: BLCA; CESC; ESCA; KIRC; KIRP; LGG; OV; THCA; STAD | MirTarget | TCGA BLCA -0.277; TCGA CESC -0.393; TCGA ESCA -0.634; TCGA KIRC -0.412; TCGA KIRP -0.668; TCGA LGG -0.296; TCGA OV -0.381; TCGA THCA -0.239; TCGA STAD -0.809 |
hsa-miR-502-3p | GLI2 | 11 cancers: BLCA; BRCA; COAD; ESCA; KIRC; LIHC; LUSC; OV; PAAD; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.452; TCGA BRCA -0.128; TCGA COAD -0.593; TCGA ESCA -0.617; TCGA KIRC -0.462; TCGA LIHC -0.332; TCGA LUSC -0.501; TCGA OV -0.201; TCGA PAAD -0.355; TCGA THCA -0.431; TCGA STAD -0.35 |
hsa-miR-502-3p | DOK6 | 10 cancers: BLCA; BRCA; COAD; KIRC; LGG; LUAD; PAAD; PRAD; STAD; UCEC | MirTarget; PITA; miRNATAP | TCGA BLCA -0.642; TCGA BRCA -0.309; TCGA COAD -0.613; TCGA KIRC -0.178; TCGA LGG -0.423; TCGA LUAD -0.161; TCGA PAAD -0.353; TCGA PRAD -0.207; TCGA STAD -0.454; TCGA UCEC -0.255 |
hsa-miR-502-3p | PPP3CA | 10 cancers: BLCA; COAD; ESCA; KIRC; KIRP; LIHC; LUAD; PRAD; THCA; STAD | MirTarget; PITA; miRNATAP | TCGA BLCA -0.155; TCGA COAD -0.1; TCGA ESCA -0.094; TCGA KIRC -0.055; TCGA KIRP -0.068; TCGA LIHC -0.21; TCGA LUAD -0.102; TCGA PRAD -0.095; TCGA THCA -0.099; TCGA STAD -0.087 |
hsa-miR-502-3p | PPP2R2C | 10 cancers: BLCA; ESCA; HNSC; KIRC; LUAD; LUSC; PAAD; PRAD; SARC; STAD | MirTarget; PITA; miRNATAP | TCGA BLCA -0.547; TCGA ESCA -1.518; TCGA HNSC -0.477; TCGA KIRC -0.56; TCGA LUAD -0.404; TCGA LUSC -0.934; TCGA PAAD -0.67; TCGA PRAD -0.174; TCGA SARC -0.777; TCGA STAD -0.553 |
hsa-miR-502-3p | EXOC5 | 9 cancers: BLCA; COAD; ESCA; HNSC; LGG; LUAD; PRAD; SARC; STAD | MirTarget | TCGA BLCA -0.083; TCGA COAD -0.083; TCGA ESCA -0.224; TCGA HNSC -0.089; TCGA LGG -0.066; TCGA LUAD -0.075; TCGA PRAD -0.062; TCGA SARC -0.064; TCGA STAD -0.124 |
hsa-miR-502-3p | TSHZ3 | 13 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; STAD | MirTarget; PITA; miRNATAP | TCGA BLCA -0.68; TCGA BRCA -0.201; TCGA COAD -0.58; TCGA ESCA -0.712; TCGA HNSC -0.355; TCGA KIRC -0.196; TCGA KIRP -0.168; TCGA LGG -0.068; TCGA LIHC -0.186; TCGA LUAD -0.182; TCGA LUSC -0.509; TCGA PAAD -0.266; TCGA STAD -0.58 |
hsa-miR-502-3p | ATXN1 | 11 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LUSC; PAAD; SARC; STAD | PITA; miRNATAP | TCGA BLCA -0.414; TCGA BRCA -0.146; TCGA COAD -0.248; TCGA ESCA -0.222; TCGA HNSC -0.134; TCGA KIRC -0.197; TCGA KIRP -0.083; TCGA LUSC -0.162; TCGA PAAD -0.212; TCGA SARC -0.123; TCGA STAD -0.301 |
hsa-miR-502-3p | ACTN1 | 15 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD; UCEC | PITA; miRNATAP | TCGA BLCA -0.401; TCGA CESC -0.275; TCGA COAD -0.176; TCGA ESCA -0.47; TCGA HNSC -0.362; TCGA KIRC -0.359; TCGA KIRP -0.162; TCGA LIHC -0.116; TCGA LUAD -0.123; TCGA LUSC -0.345; TCGA PAAD -0.277; TCGA SARC -0.638; TCGA THCA -0.454; TCGA STAD -0.446; TCGA UCEC -0.091 |
hsa-miR-502-3p | SPOCK1 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LUAD; LUSC; PAAD; THCA; STAD | PITA; miRNATAP | TCGA BLCA -0.624; TCGA BRCA -0.301; TCGA CESC -0.364; TCGA COAD -0.905; TCGA ESCA -0.944; TCGA HNSC -0.456; TCGA KIRP -0.231; TCGA LUAD -0.785; TCGA LUSC -0.685; TCGA PAAD -0.808; TCGA THCA -1.167; TCGA STAD -0.738 |
hsa-miR-502-3p | KLF12 | 10 cancers: BLCA; COAD; ESCA; LGG; LIHC; LUSC; OV; THCA; STAD; UCEC | PITA; miRNATAP | TCGA BLCA -0.489; TCGA COAD -0.611; TCGA ESCA -0.436; TCGA LGG -0.248; TCGA LIHC -0.171; TCGA LUSC -0.22; TCGA OV -0.203; TCGA THCA -0.305; TCGA STAD -0.481; TCGA UCEC -0.216 |
hsa-miR-502-3p | SH3PXD2A | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LUSC; PAAD; PRAD; THCA; STAD | PITA; miRNATAP | TCGA BLCA -0.391; TCGA BRCA -0.088; TCGA CESC -0.158; TCGA COAD -0.189; TCGA ESCA -0.292; TCGA HNSC -0.199; TCGA KIRC -0.399; TCGA LUSC -0.341; TCGA PAAD -0.198; TCGA PRAD -0.098; TCGA THCA -0.174; TCGA STAD -0.274 |
hsa-miR-502-3p | KCNQ5 | 12 cancers: BLCA; CESC; COAD; ESCA; KIRC; KIRP; LGG; LUAD; OV; PAAD; SARC; STAD | PITA; miRNATAP | TCGA BLCA -0.673; TCGA CESC -0.436; TCGA COAD -0.797; TCGA ESCA -1.746; TCGA KIRC -0.381; TCGA KIRP -0.24; TCGA LGG -0.359; TCGA LUAD -0.353; TCGA OV -0.41; TCGA PAAD -0.507; TCGA SARC -0.533; TCGA STAD -0.855 |
hsa-miR-502-3p | UBE2E2 | 10 cancers: BLCA; CESC; COAD; ESCA; KIRP; LGG; LIHC; PAAD; THCA; STAD | PITA; miRNATAP | TCGA BLCA -0.17; TCGA CESC -0.225; TCGA COAD -0.518; TCGA ESCA -0.418; TCGA KIRP -0.107; TCGA LGG -0.179; TCGA LIHC -0.27; TCGA PAAD -0.425; TCGA THCA -0.187; TCGA STAD -0.419 |
hsa-miR-502-3p | NUAK1 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; OV; PAAD; STAD; UCEC | mirMAP | TCGA BLCA -0.229; TCGA BRCA -0.265; TCGA CESC -0.234; TCGA COAD -0.399; TCGA ESCA -0.399; TCGA HNSC -0.27; TCGA KIRC -0.207; TCGA LUAD -0.315; TCGA LUSC -0.586; TCGA OV -0.184; TCGA PAAD -0.528; TCGA STAD -0.192; TCGA UCEC -0.262 |
hsa-miR-502-3p | ZCCHC24 | 10 cancers: BLCA; BRCA; COAD; ESCA; LGG; LIHC; LUSC; PAAD; STAD; UCEC | mirMAP | TCGA BLCA -0.491; TCGA BRCA -0.301; TCGA COAD -0.359; TCGA ESCA -0.39; TCGA LGG -0.267; TCGA LIHC -0.149; TCGA LUSC -0.184; TCGA PAAD -0.211; TCGA STAD -0.712; TCGA UCEC -0.154 |
hsa-miR-502-3p | AKT3 | 12 cancers: BLCA; CESC; COAD; ESCA; KIRP; LGG; LIHC; PAAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.327; TCGA CESC -0.229; TCGA COAD -0.644; TCGA ESCA -0.503; TCGA KIRP -0.14; TCGA LGG -0.218; TCGA LIHC -0.257; TCGA PAAD -0.346; TCGA SARC -0.39; TCGA THCA -0.198; TCGA STAD -0.584; TCGA UCEC -0.201 |
hsa-miR-502-3p | CSNK1A1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.141; TCGA BRCA -0.176; TCGA CESC -0.091; TCGA COAD -0.066; TCGA ESCA -0.232; TCGA HNSC -0.12; TCGA KIRC -0.131; TCGA KIRP -0.076; TCGA LIHC -0.113; TCGA LUAD -0.094; TCGA LUSC -0.086; TCGA SARC -0.059; TCGA THCA -0.11; TCGA STAD -0.089 |
hsa-miR-502-3p | ATL1 | 11 cancers: BLCA; COAD; ESCA; HNSC; LGG; LIHC; LUAD; PAAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.236; TCGA COAD -0.344; TCGA ESCA -0.361; TCGA HNSC -0.237; TCGA LGG -0.135; TCGA LIHC -0.129; TCGA LUAD -0.201; TCGA PAAD -0.195; TCGA SARC -0.332; TCGA STAD -0.478; TCGA UCEC -0.1 |
hsa-miR-502-3p | RNF145 | 9 cancers: BLCA; CESC; ESCA; KIRC; KIRP; LIHC; PAAD; PRAD; THCA | miRNATAP | TCGA BLCA -0.356; TCGA CESC -0.184; TCGA ESCA -0.236; TCGA KIRC -0.37; TCGA KIRP -0.246; TCGA LIHC -0.179; TCGA PAAD -0.114; TCGA PRAD -0.069; TCGA THCA -0.077 |
hsa-miR-502-3p | RORA | 9 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRC; LIHC; PAAD; STAD | miRNATAP | TCGA BLCA -0.142; TCGA BRCA -0.096; TCGA CESC -0.248; TCGA COAD -0.494; TCGA ESCA -0.336; TCGA KIRC -0.193; TCGA LIHC -0.266; TCGA PAAD -0.26; TCGA STAD -0.483 |
hsa-miR-502-3p | FAM131B | 11 cancers: BLCA; BRCA; HNSC; KIRC; LGG; LUAD; LUSC; OV; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.553; TCGA BRCA -0.398; TCGA HNSC -0.187; TCGA KIRC -0.163; TCGA LGG -0.248; TCGA LUAD -0.171; TCGA LUSC -0.398; TCGA OV -0.166; TCGA THCA -0.404; TCGA STAD -0.332; TCGA UCEC -0.27 |
hsa-miR-502-3p | PROM2 | 10 cancers: BRCA; CESC; ESCA; HNSC; LGG; LUAD; LUSC; PAAD; PRAD; SARC | MirTarget | TCGA BRCA -0.313; TCGA CESC -0.398; TCGA ESCA -0.44; TCGA HNSC -0.32; TCGA LGG -0.239; TCGA LUAD -0.233; TCGA LUSC -0.738; TCGA PAAD -0.772; TCGA PRAD -0.229; TCGA SARC -0.238 |
hsa-miR-502-3p | PTPRF | 10 cancers: BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LUSC; PRAD; SARC; THCA | PITA; miRNATAP | TCGA BRCA -0.062; TCGA CESC -0.128; TCGA ESCA -0.23; TCGA HNSC -0.136; TCGA KIRC -0.121; TCGA KIRP -0.192; TCGA LUSC -0.224; TCGA PRAD -0.108; TCGA SARC -0.438; TCGA THCA -0.497 |
hsa-miR-502-3p | COL12A1 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; PAAD; STAD | PITA | TCGA BRCA -0.326; TCGA CESC -0.589; TCGA COAD -0.462; TCGA ESCA -0.493; TCGA HNSC -0.529; TCGA KIRC -0.175; TCGA LIHC -0.258; TCGA LUAD -0.593; TCGA LUSC -0.857; TCGA PAAD -0.858; TCGA STAD -0.188 |
hsa-miR-502-3p | PLK2 | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; THCA; UCEC | PITA; miRNATAP | TCGA BRCA -0.206; TCGA CESC -0.757; TCGA COAD -0.258; TCGA ESCA -0.283; TCGA HNSC -0.163; TCGA KIRC -0.77; TCGA KIRP -0.456; TCGA LIHC -0.332; TCGA LUAD -0.186; TCGA LUSC -0.334; TCGA OV -0.198; TCGA THCA -0.288; TCGA UCEC -0.204 |
hsa-miR-502-3p | COL10A1 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; PAAD; THCA | miRNATAP | TCGA BRCA -0.487; TCGA CESC -0.815; TCGA COAD -0.97; TCGA ESCA -1.076; TCGA HNSC -0.865; TCGA KIRC -0.483; TCGA LIHC -0.616; TCGA LUAD -0.589; TCGA LUSC -1.177; TCGA PAAD -1.34; TCGA THCA -0.67 |
hsa-miR-502-3p | ZNF827 | 10 cancers: BRCA; COAD; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; STAD | miRNATAP | TCGA BRCA -0.268; TCGA COAD -0.196; TCGA LGG -0.293; TCGA LIHC -0.351; TCGA LUAD -0.126; TCGA LUSC -0.172; TCGA OV -0.112; TCGA PRAD -0.164; TCGA SARC -0.349; TCGA STAD -0.194 |
hsa-miR-502-3p | BHLHE41 | 13 cancers: BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LUSC; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BRCA -0.152; TCGA COAD -0.219; TCGA ESCA -0.404; TCGA HNSC -0.341; TCGA KIRC -0.892; TCGA KIRP -0.384; TCGA LUSC -0.333; TCGA PAAD -0.316; TCGA PRAD -0.16; TCGA SARC -0.175; TCGA THCA -0.575; TCGA STAD -0.335; TCGA UCEC -0.248 |
hsa-miR-502-3p | RAI14 | 10 cancers: CESC; COAD; ESCA; HNSC; KIRC; KIRP; LUSC; OV; PAAD; STAD | MirTarget; miRNATAP | TCGA CESC -0.382; TCGA COAD -0.238; TCGA ESCA -0.391; TCGA HNSC -0.36; TCGA KIRC -0.117; TCGA KIRP -0.086; TCGA LUSC -0.38; TCGA OV -0.11; TCGA PAAD -0.289; TCGA STAD -0.188 |
hsa-miR-502-3p | SLC35F3 | 10 cancers: CESC; ESCA; HNSC; KIRC; KIRP; LIHC; LUSC; PAAD; THCA; STAD | MirTarget; PITA | TCGA CESC -0.444; TCGA ESCA -1.253; TCGA HNSC -0.415; TCGA KIRC -0.341; TCGA KIRP -0.601; TCGA LIHC -0.412; TCGA LUSC -0.509; TCGA PAAD -0.549; TCGA THCA -0.592; TCGA STAD -0.547 |
hsa-miR-502-3p | CHMP1B | 9 cancers: CESC; COAD; ESCA; HNSC; LIHC; LUAD; PRAD; STAD; UCEC | MirTarget; miRNATAP | TCGA CESC -0.11; TCGA COAD -0.115; TCGA ESCA -0.118; TCGA HNSC -0.112; TCGA LIHC -0.108; TCGA LUAD -0.089; TCGA PRAD -0.093; TCGA STAD -0.164; TCGA UCEC -0.069 |
hsa-miR-502-3p | CLEC5A | 9 cancers: CESC; COAD; ESCA; HNSC; KIRC; LUSC; PAAD; THCA; UCEC | MirTarget | TCGA CESC -0.236; TCGA COAD -0.464; TCGA ESCA -0.47; TCGA HNSC -0.245; TCGA KIRC -0.733; TCGA LUSC -0.424; TCGA PAAD -0.667; TCGA THCA -0.568; TCGA UCEC -0.157 |
hsa-miR-502-3p | MARCKS | 12 cancers: CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; PAAD; PRAD; STAD | PITA | TCGA CESC -0.168; TCGA COAD -0.105; TCGA ESCA -0.181; TCGA HNSC -0.113; TCGA KIRC -0.387; TCGA KIRP -0.217; TCGA LGG -0.31; TCGA LUAD -0.127; TCGA LUSC -0.187; TCGA PAAD -0.149; TCGA PRAD -0.118; TCGA STAD -0.072 |
hsa-miR-502-3p | TMEM169 | 9 cancers: COAD; ESCA; KIRP; LGG; LUSC; PAAD; SARC; STAD; UCEC | MirTarget; miRNATAP | TCGA COAD -0.369; TCGA ESCA -0.353; TCGA KIRP -0.254; TCGA LGG -0.335; TCGA LUSC -0.291; TCGA PAAD -0.264; TCGA SARC -0.222; TCGA STAD -0.265; TCGA UCEC -0.246 |
hsa-miR-502-3p | SERTAD2 | 9 cancers: ESCA; HNSC; KIRC; KIRP; LUAD; PAAD; SARC; THCA; STAD | PITA; miRNATAP | TCGA ESCA -0.378; TCGA HNSC -0.148; TCGA KIRC -0.183; TCGA KIRP -0.15; TCGA LUAD -0.083; TCGA PAAD -0.166; TCGA SARC -0.112; TCGA THCA -0.275; TCGA STAD -0.172 |
hsa-miR-502-3p | LDHA | 9 cancers: ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; PAAD; PRAD; THCA | miRNATAP | TCGA ESCA -0.211; TCGA HNSC -0.158; TCGA KIRC -0.529; TCGA KIRP -0.354; TCGA LUAD -0.191; TCGA LUSC -0.18; TCGA PAAD -0.297; TCGA PRAD -0.125; TCGA THCA -0.083 |
Enriched cancer pathways of putative targets